{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:15:44Z","timestamp":1794014144932,"version":"4.8.0"},"reference-count":93,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:sec id=\"ab-coi250051-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Patient-reported outcomes (PROs) are health data that are collected directly from patients to assess symptoms, functional status, and quality of life. While studies have reported associations between PROs and survival, the prognostic significance of specific PRO domains has not been systematically quantified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250051-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between baseline PROs and overall survival (OS) in patients with cancer and quantify the prognostic significance of various PRO domains through a systematic review and meta-analysis of randomized clinical trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250051-6\">\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A systematic literature search of PubMed (MEDLINE), Ovid Embase, and the Cochrane Library was conducted to identify eligible studies published between January 1, 2000, and June 1, 2024. The data were analyzed on January 15, 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250051-7\">\n                    <jats:title>Study Selection<\/jats:title>\n                    <jats:p>Eligible studies were prospective RCTs that enrolled adult patients with cancer (18 years or older) that included at least 1 baseline PRO measure, reported OS as an outcome, and conducted multivariate analyses that adjusted for clinical and disease-related confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250051-8\">\n                    <jats:title>Data Extraction and Synthesis<\/jats:title>\n                    <jats:p>Data from eligible RCTs were extracted independently and in duplicate by 4 reviewers. Studies using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire were meta-analyzed using a random-effects model with an inverse variance\u2013weighted approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250051-9\">\n                    <jats:title>Main Outcome and Measure<\/jats:title>\n                    <jats:p>The primary outcome was the association between baseline PROs and OS reported using pooled hazard ratios (HRs) and 95% CIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250051-10\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 69 RCTs comprising 44\u202f030 patients were included in the systematic review, with 31 RCTs (44.9%) meeting criteria for the meta-analysis. Higher global health status scores and quality of life were associated with improved OS (hazard ratio [HR], 0.99; 95% CI, 0.98-0.99). Among functional scales, physical functioning (HR, 0.94; 95% CI, 0.92-0.96) and role functioning (HR, 0.96; 95% CI, 0.94-0.98) were associated with improved OS. Conversely, higher symptom burden, including nausea and vomiting (HR, 1.12; 95% CI, 1.04-1.21), fatigue (HR, 1.05; 95% CI, 1.00-1.10), and pain (HR, 1.07; 95% CI, 1.04-1.11), was associated with worse OS. The overall pooled effect demonstrated that increasing individual symptom severity was associated with higher mortality risk (HR, 1.03; 95% CI, 1.01-1.04). The Egger test showed no evidence of publication bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250051-11\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis found that PROs offer independent prognostic information for cancer survival. These findings support the integration of PRO assessments into clinical decision-making and risk stratification in oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.3153","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:00:23Z","timestamp":1757602823000},"page":"1303","source":"Crossref","is-referenced-by-count":31,"title":["Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer"],"prefix":"10.1001","volume":"11","author":[{"given":"Ryan S.","family":"Huang","sequence":"first","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chen","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Benour","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Cortez","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlton","family":"Johnny","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bezjak","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Olson","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Department of Radiation Oncology, BC Cancer Vancouver, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Raman","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Department of Radiation Oncology, BC Cancer Vancouver, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"coi250051r1","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1093\/annonc\/mdv181","article-title":"Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors.","volume":"26","author":"Howell","year":"2015","journal-title":"Ann Oncol"},{"issue":"7","key":"coi250051r2","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms.","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"coi250051r3","doi-asserted-by":"publisher","first-page":"e685","DOI":"10.1016\/S1470-2045(19)30656-4","article-title":"Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review.","volume":"20","author":"Mierzynska","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"coi250051r4","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1200\/JCO.2007.13.3439","article-title":"The prognostic significance of patient-reported outcomes in cancer clinical trials.","volume":"26","author":"Gotay","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi250051r5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jval.2020.10.017","article-title":"Patient-reported outcomes as independent prognostic factors for survival in oncology: systematic review and meta-analysis.","volume":"24","author":"Efficace","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"coi250051r6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12955-019-1220-z","article-title":"The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis.","volume":"17","author":"Rivera","year":"2019","journal-title":"Health Qual Life Outcomes"},{"issue":"71","key":"coi250051r7","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"coi250051r8","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/S0959-8049(01)00448-8","article-title":"Quality of life research within the EORTC-the EORTC QLQ-C30.","volume":"38","author":"Fayers","year":"2002","journal-title":"Eur J Cancer"},{"issue":"5","key":"coi250051r9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"coi250051r10","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7109","key":"coi250051r11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"36","key":"coi250051r12","doi-asserted-by":"publisher","first-page":"5770","DOI":"10.1200\/JCO.2007.12.5294","article-title":"Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? a prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.","volume":"25","author":"Bottomley","year":"2007","journal-title":"J Clin Oncol"},{"issue":"34","key":"coi250051r13","doi-asserted-by":"publisher","first-page":"5816","DOI":"10.1200\/JCO.2009.23.7420","article-title":"Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.","volume":"27","author":"Movsas","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi250051r14","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00520-012-1569-6","article-title":"Health-related quality of life and inflammatory markers in malignant pleural mesothelioma.","volume":"21","author":"Kao","year":"2013","journal-title":"Support Care Cancer"},{"issue":"9","key":"coi250051r15","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/JTO.0b013e3181ae27f5","article-title":"Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non\u2013small cell lung cancer.","volume":"4","author":"Qi","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"10","key":"coi250051r16","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1038\/bjc.2014.208","article-title":"Does change in health-related quality of life score predict survival? analysis of EORTC 08975 lung cancer trial.","volume":"110","author":"Ediebah","year":"2014","journal-title":"Br J Cancer"},{"issue":"2","key":"coi250051r17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/JTO.0000000000000277","article-title":"Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.","volume":"10","author":"Spigel","year":"2015","journal-title":"J Thorac Oncol"},{"key":"coi250051r18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejca.2015.10.004","article-title":"Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.","volume":"52","author":"Fiteni","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"coi250051r19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamaoncol.2015.3969","article-title":"Quality of life analysis of a radiation dose-escalation study of patients with non\u2013small-cell lung cancer: a secondary analysis of the Radiation Therapy Oncology Group 0617 randomized clinical trial.","volume":"2","author":"Movsas","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"coi250051r20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.lungcan.2012.09.002","article-title":"Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.","volume":"78","author":"Reck","year":"2012","journal-title":"Lung Cancer"},{"issue":"11","key":"coi250051r21","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/annonc\/mdl183","article-title":"Is a patient\u2019s self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? a multivariate analysis of prognostic factors of EORTC study 08975.","volume":"17","author":"Efficace","year":"2006","journal-title":"Ann Oncol"},{"issue":"11","key":"coi250051r22","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1002\/ijc.33133","article-title":"Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.","volume":"147","author":"Hopkins","year":"2020","journal-title":"Int J Cancer"},{"issue":"28","key":"coi250051r23","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.1200\/JCO.2005.02.527","article-title":"Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.","volume":"23","author":"Maione","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi250051r24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/cncr.28382","article-title":"A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites.","volume":"120","author":"Quinten","year":"2014","journal-title":"Cancer"},{"issue":"5","key":"coi250051r25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/jjco\/hyaa257","article-title":"Prognostic impact of geriatric assessment in elderly patients with non\u2013small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A).","volume":"51","author":"Katayama","year":"2021","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"coi250051r26","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1002\/cncr.23080","article-title":"Emotional well-being does not predict survival in head and neck cancer patients: a Radiation Therapy Oncology Group study.","volume":"110","author":"Coyne","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"coi250051r27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ijrobp.2007.06.024","article-title":"Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis.","volume":"70","author":"Siddiqui","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"coi250051r28","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1200\/JCO.2008.20.0295","article-title":"Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy.","volume":"27","author":"Meyer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi250051r29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.oraloncology.2012.02.016","article-title":"Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy.","volume":"48","author":"Urba","year":"2012","journal-title":"Oral Oncol"},{"issue":"4","key":"coi250051r30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.ijrobp.2016.08.003","article-title":"Quality of life and performance status from a substudy conducted within a prospective phase 3 randomized trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for locally advanced head and neck carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.","volume":"97","author":"Truong","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"coi250051r31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ijrobp.2016.07.020","article-title":"Quality of life and performance status from a substudy conducted within a prospective phase 3 randomized trial of concurrent standard radiation versus accelerated radiation plus cisplatin for locally advanced head and neck carcinoma: NRG Oncology RTOG 0129.","volume":"97","author":"Xiao","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi250051r32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2021.07.034","article-title":"Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.","volume":"156","author":"Szturz","year":"2021","journal-title":"Eur J Cancer"},{"issue":"9","key":"coi250051r33","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/sj.bjc.6605929","article-title":"Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy.","volume":"103","author":"Bernhard","year":"2010","journal-title":"Br J Cancer"},{"issue":"2","key":"coi250051r34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jpainsymman.2011.09.001","article-title":"Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).","volume":"43","author":"Romanus","year":"2012","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"coi250051r35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/JCO.2012.44.4869","article-title":"Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial.","volume":"31","author":"Gourgou-Bourgade","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi250051r36","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s11136-015-1198-x","article-title":"Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology.","volume":"25","author":"Diouf","year":"2016","journal-title":"Qual Life Res"},{"issue":"6","key":"coi250051r37","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.pan.2016.08.013","article-title":"Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.","volume":"16","author":"Vickers","year":"2016","journal-title":"Pancreatology"},{"issue":"9","key":"coi250051r38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183288","article-title":"Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ ACCORD 11 randomized trial.","volume":"12","author":"Lambert","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"coi250051r39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41391-022-00529-2","article-title":"Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer\u2014exploratory analysis of LATITUDE study.","volume":"26","author":"Roy","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"coi250051r40","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2007.12.3117","article-title":"Validation of patient\u2019s self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.","volume":"26","author":"Efficace","year":"2008","journal-title":"J Clin Oncol"},{"key":"coi250051r41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1477-7525-12-69","article-title":"Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? the results of the GERCOR OPTIMOX 1 study.","volume":"12","author":"Diouf","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"coi250051r42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.07.013","article-title":"The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients.","volume":"66","author":"Mol","year":"2016","journal-title":"Eur J Cancer"},{"issue":"10","key":"coi250051r43","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0959-8049(02)00098-9","article-title":"Baseline quality of life predicts survival in patients with advanced colorectal cancer.","volume":"38","author":"Maisey","year":"2002","journal-title":"Eur J Cancer"},{"issue":"1","key":"coi250051r44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00520-015-2792-8","article-title":"Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer.","volume":"24","author":"Schofield","year":"2016","journal-title":"Support Care Cancer"},{"issue":"1","key":"coi250051r45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/02841860903369540","article-title":"Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet.","volume":"49","author":"Comella","year":"2010","journal-title":"Acta Oncol"},{"issue":"15","key":"coi250051r46","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1200\/JCO.2007.15.0367","article-title":"Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.","volume":"26","author":"Halabi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi250051r47","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1093\/annonc\/mdt194","article-title":"Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.","volume":"24","author":"Bahl","year":"2013","journal-title":"Ann Oncol"},{"key":"coi250051r48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.09.035","article-title":"The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: exploratory analyses of AFFIRM and PREVAIL studies.","volume":"87","author":"Beer","year":"2017","journal-title":"Eur J Cancer"},{"issue":"19","key":"coi250051r49","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1200\/JCO.2004.07.089","article-title":"Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? a pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group.","volume":"22","author":"Collette","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi250051r50","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.3390\/cancers13061284","article-title":"Pain progression at initiation of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): a post hoc analysis of the PROSELICA study.","volume":"13","author":"Delanoy","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"coi250051r51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2017.08.035","article-title":"The phase 3 COU-AA-302 study of abiraterone acetate plus prednisone in men with chemotherapy-naive metastatic castration-resistant prostate cancer: stratified analysis based on pain, prostate-specific antigen, and Gleason score.","volume":"74","author":"Miller","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"coi250051r52","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ygyno.2007.08.088","article-title":"The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.","volume":"108","author":"Carey","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"8","key":"coi250051r53","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/annonc\/mdx229","article-title":"Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy.","volume":"28","author":"Roncolato","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"coi250051r54","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1365-2036.2007.03589.x","article-title":"Factors predicting survival in patients with advanced oesophageal cancer: a prospective multicentre evaluation.","volume":"27","author":"Bergquist","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"coi250051r55","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jhep.2012.11.019","article-title":"The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma.","volume":"58","author":"Diouf","year":"2013","journal-title":"J Hepatol"},{"issue":"36","key":"coi250051r56","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1200\/JCO.2007.11.1476","article-title":"Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.","volume":"25","author":"Mauer","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi250051r57","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/sj.bjc.6603876","article-title":"The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study.","volume":"97","author":"Mauer","year":"2007","journal-title":"Br J Cancer"},{"issue":"8","key":"coi250051r58","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/cam4.734","article-title":"Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.","volume":"5","author":"Paquette","year":"2016","journal-title":"Cancer Med"},{"issue":"2","key":"coi250051r59","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12032-011-9844-9","article-title":"Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.","volume":"29","author":"Svensson","year":"2012","journal-title":"Med Oncol"},{"issue":"2","key":"coi250051r60","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11136-008-9307-8","article-title":"Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy.","volume":"17","author":"Park","year":"2008","journal-title":"Qual Life Res"},{"issue":"6","key":"coi250051r61","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3109\/0284186X.2013.789140","article-title":"Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure: a report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.","volume":"52","author":"Brandberg","year":"2013","journal-title":"Acta Oncol"},{"issue":"1","key":"coi250051r62","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijrobp.2015.04.016","article-title":"Prospective longitudinal assessment of quality of life for liver cancer patients treated with stereotactic body radiation therapy.","volume":"93","author":"Klein","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"coi250051r63","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ejca.2004.01.014","article-title":"Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.","volume":"40","author":"Efficace","year":"2004","journal-title":"Eur J Cancer"},{"key":"coi250051r64","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2021.101707","article-title":"Does baseline quality of life predict the occurrence of complications in resectable esophageal cancer?","volume":"40","author":"Sheng","year":"2022","journal-title":"Surg Oncol"},{"issue":"16","key":"coi250051r65","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO.2004.02.060","article-title":"Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study.","volume":"22","author":"Efficace","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi250051r66","doi-asserted-by":"publisher","first-page":"132","DOI":"10.5230\/jgc.2017.17.e16","article-title":"Prognostic factor analysis of overall survival in gastric cancer from two phase III studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data.","volume":"17","author":"Fuchs","year":"2017","journal-title":"J Gastric Cancer"},{"issue":"7","key":"coi250051r67","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/onco.13806","article-title":"Patient-reported outcomes predict progression-free survival of patients with advanced breast cancer treated with abemaciclib.","volume":"26","author":"Badaoui","year":"2021","journal-title":"Oncologist"},{"issue":"12","key":"coi250051r68","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2004.08.154","article-title":"Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer\u2013pooled analysis from three multicenter, randomized, controlled trials using individual patient data.","volume":"22","author":"Chau","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi250051r69","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1200\/JCO.2003.04.166","article-title":"Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer.","volume":"21","author":"Roychowdhury","year":"2003","journal-title":"J Clin Oncol"},{"issue":"32","key":"coi250051r70","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1200\/JCO.2013.49.6067","article-title":"Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi250051r71","doi-asserted-by":"publisher","first-page":"261","DOI":"10.6004\/jnccn.2021.7057","article-title":"Quality of life is associated with survival in patients with gastric cancer: results from the randomized CRITICS trial.","volume":"20","author":"van Amelsfoort","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"coi250051r72","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3233\/BLC-211613","article-title":"Association between patient-reported outcomes and survival in patients with advanced urothelial carcinoma treated with atezolizumab.","volume":"8","author":"Tan","year":"2022","journal-title":"Bladder Cancer"},{"issue":"2","key":"coi250051r73","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ygyno.2012.01.047","article-title":"Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study.","volume":"125","author":"Chase","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"3","key":"coi250051r74","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ygyno.2011.11.032","article-title":"The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group study.","volume":"124","author":"von Gruenigen","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"1","key":"coi250051r75","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ygyno.2017.07.121","article-title":"Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: an ancillary data analysis of the NRG Oncology\/Gynecologic Oncology Group (GOG-0218) study.","volume":"147","author":"Phippen","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"6","key":"coi250051r76","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/14737167.2019.1596027","article-title":"Prognostic impact of baseline quality of life status among patients with advanced gastric cancer; results from two randomized studies.","volume":"19","author":"Abdel-Rahman","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"coi250051r77","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12955-016-0449-z","article-title":"Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer.","volume":"14","author":"Smyth","year":"2016","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"coi250051r78","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1245\/s10434-009-0731-y","article-title":"Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer.","volume":"17","author":"van Heijl","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"coi250051r79","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s11136-008-9365-y","article-title":"Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials.","volume":"17","author":"Bonnetain","year":"2008","journal-title":"Qual Life Res"},{"issue":"1","key":"coi250051r80","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00432-008-0438-7","article-title":"Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.","volume":"135","author":"Herrmann","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"coi250051r81","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110216","article-title":"Dose-response of localized renal cell carcinoma after stereotactic body radiation therapy: a meta-analysis.","volume":"194","author":"Huang","year":"2024","journal-title":"Radiotherapy and Oncology"},{"issue":"6","key":"coi250051r82","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jclinepi.2003.11.010","article-title":"Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivors.","volume":"57","author":"Courneya","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"coi250051r83","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12885-024-12267-w","article-title":"Pretreatment quality of life and survival in patients with lung cancer: a systematic review and meta-analysis.","volume":"24","author":"Okayama","year":"2024","journal-title":"BMC Cancer"},{"issue":"2","key":"coi250051r84","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/gut.49.2.227","article-title":"The prognostic value of quality of life scores during treatment for oesophageal cancer.","volume":"49","author":"Blazeby","year":"2001","journal-title":"Gut"},{"issue":"7","key":"coi250051r85","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s11136-014-0895-1","article-title":"Role functioning is associated with survival in patients with hepatocellular carcinoma.","volume":"24","author":"Meier","year":"2015","journal-title":"Qual Life Res"},{"issue":"8","key":"coi250051r86","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00520-023-07978-y","article-title":"Prevalence and predictors of long-delayed (&gt;120 h) chemotherapy-induced nausea and vomiting (CINV)\u2014a systematic review and individual patient data meta-analysis.","volume":"31","author":"Chow","year":"2023","journal-title":"Support Care Cancer"},{"issue":"23","key":"coi250051r87","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1200\/JCO.2007.15.9533","article-title":"Evidence-based recommendations for cancer nausea and vomiting.","volume":"26","author":"Naeim","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi250051r88","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00520-017-3614-y","article-title":"A systematic review of the impact of pain on overall survival in patients with cancer.","volume":"25","author":"Zylla","year":"2017","journal-title":"Support Care Cancer"},{"issue":"7","key":"coi250051r89","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.clon.2021.01.008","article-title":"Comparing the ability of physician-reported versus patient-reported performance status to predict survival in a population-based cohort of newly diagnosed cancer patients.","volume":"33","author":"Al-Rashdan","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"coi250051r90","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1200\/OP.20.00515","article-title":"Comparing clinician-assessed and patient-reported performance status for predicting morbidity and mortality in patients with advanced cancer receiving chemotherapy.","volume":"17","author":"Wood","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"coi250051r91","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/jnci\/djad268","article-title":"The impact of multidisciplinary cancer conferences on overall survival: a meta-analysis.","volume":"116","author":"Huang","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"coi250051r92","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2019.12.007","article-title":"Artificial intelligence in cancer diagnosis and prognosis: opportunities and challenges.","volume":"471","author":"Huang","year":"2020","journal-title":"Cancer Lett"},{"issue":"21","key":"coi250051r93","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2838863\/jamaoncology_huang_2025_oi_250051_1763138465.88341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:01:40Z","timestamp":1763654500000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2838863"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":93,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.3153","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}